spacer
home > ict > winter 2009 > strategic planning
PUBLICATIONS
International Clinical Trials

Strategic Planning

The pharmaceutical industry is experiencing tough times, facing both economic and regulatory pressures, with increasing demands for improved safety data and comparative efficacy studies, as well as late-stage pipeline failures and non-approvals by US and EU regulatory agencies. However, pharma has a wide variety of R&D strategies at its disposal to develop drug candidates faster and more efficiently. These can be implemented in isolation, but work more effectively in combination so as to optimise the linical trial process and increase the chance of clinical, and ultimately commercial, success. However, without efficient management and communication, the speed to market of a novel drug is likely to suffer.

CURRENT PROBLEMS WITH PHARMA R&D

In the increasingly competitive and cost-conscious pharmaceutical environment, it is important that pharma companies develop their pipeline products as quickly and cheaply as possible, while ensuring that they receive marketing approval as well as authorisation from the relevant reimbursement agencies. Failure to do so can have a significant economic impact and lead to company restructuring in order to balance the financial loss of drugs failing to reach the market (1).

During 2008, the number of drugs in Phase I clinical development was on the rise, but at the same time clinical trial success rates and the approval rate for new molecular entities (NMEs) were comparably low. In 2007, the FDA approved only 18 new drugs, the lowest number in 24 years (2). The number approved in 2008 was little better at 24 new approvals (3).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Alistair Sinclair is a Senior Analyst in the Strategic Intelligence team at Datamonitor. After joining in 2003, he worked for three years in the Central Nervous System Healthcare team, producing a number of market analysis reports, focusing particularly on psychiatry drug markets. Alistair moved to the Strategic Intelligence team in 2006, and has since produced reports on a wide variety of strategic issues including lifecycle management, corporate strategies, pricing and reimbursement, sales and marketing, R&D and the emerging markets. Alistair holds a BSc from the University of Edinburgh in Medical Microbiology, and an MSc from UCL and KCMC University, Tanzania. He has also worked at the Health Protection Agency, and has published a number of papers from his research. Email: asinclair@datamonitor.com

 

spacer
Alistair Sinclair
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Smart Bioprocessing with the new Eppendorf Control System

Hamburg, February 12, 2020 Working with flexible systems that evolve with the changing needs in a lab is indispensable. With the SciVario twin, Eppendorf, a key life science company, introduces its latest bioreactor control system for small- and bench-scale applications. The intelligent controller and new, innovative bay-drawer system enables the exchange of standardized modules to flexibly adapt the controller to the changing requirements in a laboratory.
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement